Eli Lilly

OverviewSuggest Edit

Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products. It offers diabetes and endocrinology, immunology, neuroscience, oncology, and other products. Its products are distributed through wholesalers that serve pharmacies, physicians, and other health care professionals and hospitals.
TypePublic
Founded1876
HQIndianapolis, IN, US
Websitelilly.com
Employee Ratings4
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2021)35,000
Job Openings930
Revenue (FY, 2021)$28.3 B(+16%)
Share Price (Jun 2022)$325.6(+5%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Eli Lilly

David A. Ricks

David A. Ricks

Chairman and Chief Executive Officer
Anat Ashkenazi

Anat Ashkenazi

Senior Vice President and Chief Financial Officer
Stephen F. Fry

Stephen F. Fry

Senior Vice President, Human Resources and Diversity
Johna L. Norton

Johna L. Norton

Senior Vice President, Global Quality
Leigh Ann Pusey

Leigh Ann Pusey

Senior Vice President, Corporate Affairs and Communications
Daniel M. Skovronsky

Daniel M. Skovronsky

Senior Vice President and Chief Scientific and Medical Officer
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Branchburg, Cambridge, New York and in 43 other locations
Indianapolis, IN, US (HQ)
893 Delaware St
Branchburg, NJ, US
33 Imclone Dr
Cambridge, MA, US
450 Kendall St
Indianapolis, IN, US
1223 W Morris St
Indianapolis, IN, US
1500 S Harding St
New York, NY, US
450 E 29th St 12th floor
Show all (49)

Eli Lilly Financials and Metrics

Eli Lilly Revenue

Embed Graph
View revenue for all periods
Eli Lilly's revenue was reported to be $28.32 b in FY, 2021 which is a 15.4% increase from the previous period.
USD

Revenue (Q1, 2022)

7.8b

Gross profit (Q1, 2022)

5.7b

Net income (Q1, 2022)

1.9b

Market capitalization (24-Jun-2022)

309.4b

Closing stock price (24-Jun-2022)

325.6

Cash (30-Sept-2021)

3.8b

EV

322.7b
Eli Lilly's current market capitalization is $309.4 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

22.3b24.5b28.3b

Revenue growth, %

(9%)10%15%

Cost of goods sold

4.7b5.5b7.3b

Gross profit

17.6b19.1b21.0b
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

5.9b5.5b5.7b6.8b6.7b6.8b7.8b

Cost of goods sold

1.2b1.2b1.3b1.9b2.0b1.4b2.1b

Gross profit

4.6b4.3b4.4b4.9b4.8b5.3b5.7b

Gross profit Margin, %

79%78%77%72%71%79%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.8b3.9b3.7b4.6b6.5b8.0b2.3b3.7b

Accounts Receivable

588.4m566.7m558.6m736.9m4.5b5.2b4.5b5.9b

Prepaid Expenses

1.4b2.1b2.5b2.9b

Inventories

2.9b2.7b3.4b3.6b4.5b4.1b3.2b4.0b
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q4, 2010Q1, 2011Q2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q4, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

123.5k5.2b5.9b6.0b6.5b6.1b6.6b5.9b4.1b4.3b5.3b4.0b3.9b3.8b4.4b3.9b3.8b3.2b3.1b3.3b3.2b2.3b3.2b3.5b2.6b3.1b3.7b3.1b6.8b9.0b2.0b2.3b1.6b1.7b2.4b3.6b3.0b3.2b3.8b

Accounts Receivable

3.2b3.1b3.3b3.5b3.7b3.8b3.5b3.6b3.4b3.2b3.3b3.3b3.4b3.6b3.4b3.0b3.2b3.1b3.1b3.3b3.4b3.6b3.9b3.8b4.0b4.3b4.4b4.5b4.8b4.9b4.2b4.6b4.4b5.1b4.8b4.9b5.6b5.8b5.9b

Prepaid Expenses

1.0b1.1b1.2b608.9m1.1b867.3m799.1m654.9m998.5m953.3m790.1m822.3m987.9m988.9m853.4m1.1b1.1b821.5m797.0m730.1m762.4m792.0m789.5m756.5m821.6m1.0b1.1b1.6b1.7b1.9b2.2b2.3b2.4b2.8b3.1b3.2b3.2b3.3b3.1b

Inventories

2.5b2.2b2.7b2.5b2.8b2.9b2.5b2.3b2.4b2.3b2.6b2.6b2.6b2.7b3.0b3.0b3.2b2.8b3.0b3.3b3.4b3.7b3.8b3.9b4.0b4.3b4.4b4.6b4.2b4.1b3.1b3.2b3.1b3.1b3.3b3.6b3.7b3.8b3.9b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

3.2b8.3b6.2b

Depreciation and Amortization

1.6b1.2b1.3b

Inventories

7.8m(258.7m)(533.4m)

Accounts Payable

(284.5m)(477.7m)1.3b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

4.2b5.6b6.8b1.5b2.9b4.1b1.4b2.7b3.9b

Depreciation and Amortization

356.5m603.9m891.9m273.6m598.0m956.4m350.3m719.6m1.1b

Cash From Operating Activities

311.3m1.4b2.9b382.4m2.9b4.7b1.7b3.5b5.1b

Purchases of PP&E

(203.7m)(444.0m)(707.4m)(258.3m)(540.1m)(933.2m)(300.3m)(681.6m)(1.0b)
USDQ1, 2010

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.6 x
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2021

Countries

125125125125120120

Phase III Trials Products

8717197191513

Projects in R&D Pipeline

57576566

Phase I Trials Products

212227

Eli Lilly Acquisitions / Subsidiaries

Company NameDateDeal Size
Protomer TechnologiesJuly 14, 2021$1 b
Prevail Therapeutics Inc.January 01, 2021$880 m
Disarm TherapeuticsOctober 15, 2020$135 m
Disarm TherapeuticsOctober 15, 2020$135 m
DermiraJanuary 10, 2020$849.3 m
DermiraJanuary 10, 2020$1.1 b
Loxo OncologyJanuary 07, 2019$6.92 b
AurKa PharmaMay 15, 2018$575 m
ARMO BioSciences IncMay 11, 2018$1.6 b
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Show more

Eli Lilly Revenue Breakdown

Embed Graph

Eli Lilly revenue breakdown by business segment: 44.2% from Diabetes, 19.1% from Oncology, 11.8% from Immunology, 5.6% from Neuroscience and 19.3% from Other

Eli Lilly revenue breakdown by geographic segment: 8.4% from Japan, 5.9% from China , 16.9% from Europe, 9.5% from Other foreign countries and 59.4% from United States

Eli Lilly Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Eli Lilly Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Eli Lilly Online and Social Media Presence

Embed Graph

Eli Lilly Company Culture

  • Overall Culture

    A-

    74/100

  • CEO Rating

    A-

    76/100

  • Compensation

    A-

    76/100

  • Diversity

    C+

    68/100

Learn more on Comparably

Eli Lilly News and Updates

Thinking about trading options or stock in Eli Lilly, Centene Corp, Snowflake, Apple, or Winnebago?

NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, CNC, SNOW, AAPL, and WGO. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC

- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada -

Global Therapeutic Proteins Market Report 2022-2031 Featuring Major Players - Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche

DUBLIN, June 20, 2022 /PRNewswire/ -- The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering. The global therapeutic proteins market is expected to grow from $100.06 billion in 2021 to...

Eli Lilly And Parexel Talk About The ROI Of Practical AI

Practical AI is the successful, measurable, business use of learning from data.

Stocks making the biggest moves midday: Sunrun, Eli Lilly, DiDi Global, CrowdStrike and more

These are the stocks posting the largest moves in midday trading.

Eli Lilly stock pulls back from record high after disclosing sales by largest shareholder

Shares of Eli Lilly & Co. fell 4.0% in afternoon trading Tuesday, to pullback from the previous session's record close, after the drug maker disclosed that its largest shareholder sold nearly $64 million worth of its shares. In a Form 4 filing with the Securities and Exchange Commission, the co…
Show more

Eli Lilly Frequently Asked Questions

  • When was Eli Lilly founded?

    Eli Lilly was founded in 1876.

  • Who are Eli Lilly key executives?

    Eli Lilly's key executives are David A. Ricks, Anat Ashkenazi and Stephen F. Fry.

  • How many employees does Eli Lilly have?

    Eli Lilly has 35,000 employees.

  • What is Eli Lilly revenue?

    Latest Eli Lilly annual revenue is $28.3 b.

  • What is Eli Lilly revenue per employee?

    Latest Eli Lilly revenue per employee is $809.1 k.

  • Who are Eli Lilly competitors?

    Competitors of Eli Lilly include Shionogi, Boehringer Ingelheim and Sanofi.

  • Where is Eli Lilly headquarters?

    Eli Lilly headquarters is located at 893 Delaware St, Indianapolis.

  • Where are Eli Lilly offices?

    Eli Lilly has offices in Indianapolis, Branchburg, Cambridge, New York and in 43 other locations.

  • How many offices does Eli Lilly have?

    Eli Lilly has 49 offices.